ARTL Artelo Biosciences, Inc.
$2.20▲ +0.00%
Healthcare
Other
Volume 30.5K
Avg Volume (10D) 36.9K
Key Metrics & Fundamentals
Market Cap
$1.21M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.10 - 179.19
% vs 50 MA
-51.54%
% vs 200 MA
-90.15%
RSI-14
26.7
MACD Histogram
+0.0200
Beta (1Y vs SPY)
-1.92
Free Cash Flow
-$5.03M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$2.46M
COGS
–
Operating Exp
$2.51M
Operating Income
-$2.51M
EBIT
-$2.51M
Pretax Income
-$2.43M
Net Income
-$2.43M
EPS (Diluted)
-0.89
Price & Volume History
Loading chart…
Recent News
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
GlobeNewswire · Oct 26, 2026 7:55 AM ET
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
GlobeNewswire · Oct 7, 2026 8:48 AM ET
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
GlobeNewswire · Sep 23, 2026 7:33 AM ET
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
GlobeNewswire · Sep 16, 2026 7:30 AM ET
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 8, 2026 9:00 AM ET
Artelo Biosciences Announces Reverse Stock Split
GlobeNewswire · Aug 27, 2026 8:00 AM ET
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
GlobeNewswire · Aug 20, 2026 8:52 AM ET
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
GlobeNewswire · Aug 17, 2026 8:52 AM ET
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
GlobeNewswire · Aug 13, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ARTL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.